Chemotherapy In Combined Treatment Research Articles

Safety assessment of preventive pressurized intraperitoneal aerosol chemotherapy in combined treatment of gastric cancer: preliminary results

Purpose of the study. Preventive pressurised intraperitoneal aerosol chemotherapy (PIPAC) safety assessment in the combined treatment of gastric cancer (GC).Patients and methods. The study included 48 patients with morphologically confirmed resectable GC and cardio esophageal transition, having at least one criterion that is a predictor of the development of peritoneal carcinomatosis, e. g. tumor spread to the serous layer (≥ T4a), diffuse tumor type, affected regional lymph nodes, large tumor, young age (up to 45 years), subtotally and totally affected stomach. 36 out of those patients received treatment according to the protocol. All patients received 4 cycles of neoadjuvant chemotherapy according to the FLOT scheme, radical surgical treatment in combination with a PIPAC session, 4 cycles of adjuvant chemotherapy according to the FLOT scheme. The safety assessment was carried out according to the classification of surgical complications according to Clavien-D indo and the international scale for toxicity scaling NCI–CTCAE v5.0.Results. Postoperative complications were diagnosed in 25 %, >III grade complications were revealed in 11 % of cases according to the Clavien-D indo classification. The postoperative mortality rate was 0 %.Conclusion. Preventive PIPAC of locally advanced GC and CET in combined treatment is a reproducible and safe method, which is characterized by the absence of an increase in the number of postoperative complications and mortality rate.

Evaluation of the results of treatment in patients with locally common forms of ovarian cancer in Andijan Regional Oncological Dispensery

The article deals with the treatment and the results of a locally common forms of ovarian cancer. The study included registered in Andijan Regional Oncological Dispensery histologically verified patients with ovarian cancer. The purpose of this section of our study is to evaluate the effectiveness of various schemes of neoadjuvant chemotherapy in combined treatment of patients with locally advanced ovarian cancer. Also, long-term treatment results are obtained depending on the different schemes poliochemotherapy

P63 Intra-arterial chemotherapy in combined treatment of patients with SCC of the oral cavity (stage III, IV)

P63 Intra-arterial chemotherapy in combined treatment of patients with SCC of the oral cavity (stage III, IV)

Endobronchial chemotherapy in combined treatment for non-small cell lung cancer: Jackevicius A, Cicenas S, Aleknavicius E. Department of Thoracic Surgery, Lithanian Oncological Center, Santariskiu 1, 2600 Vilnius. Radiol Oncol 1994;28:398–402

Endobronchial chemotherapy in combined treatment for non-small cell lung cancer: Jackevicius A, Cicenas S, Aleknavicius E. Department of Thoracic Surgery, Lithanian Oncological Center, Santariskiu 1, 2600 Vilnius. Radiol Oncol 1994;28:398–402

Pharmacokinetics of amsacrine in patients receiving combined chemotherapy for treatment of acute myelogenous leukemia.

The pharmacokinetics of amsacrine have been studied after the first and third infusions (200 mg . m-2) in 10 patients receiving combined chemotherapy for the treatment of acute myelogenous leukaemia (AML). Postinfusion amsacrine elimination was best described by a biexponential expression with a mean t1/2 alpha of 0.8 h and a terminal t1/2 beta of 5.3 h. After the third infusion there was a significant reduction (P less than 0.05) in the plasma clearance (Cl) and a prolongation of the terminal half-life (t1/2 beta) (P less than 0.01), but no change in the initial half-life (T1/2 alpha) or volume of distribution (Vd). No significant overall changes were recorded in any of the biochemical indices of renal or hepatic function between the first and third infusions, but the patient who exhibited the largest reduction in Cl showed a marked increase in AST levels and a reduction in albumin concentration. Two distinct groups were apparent after the first infusion, patients with a Cl greater than 294 and those with a Cl less than 208 ml . h-1 . kg-1. The latter patients were significantly older (P less than 0.05), and four of the five had subnormal albumin concentrations. Urinary determination of amsacrine indicated that renal elimination plays a minor role in the total clearance of this drug. Amsacrine was also found to be highly bound to plasma proteins (96.4%-97.7%), but changes in binding were not responsible for the reduced Cl and prolonged t1/2 beta observed between the first and third infusions. We suggest that the elimination of amsacrine may be susceptible to small changes in hepatic function, perhaps due to the high amsacrine concentrations (5-18 mumol . l-1) achieved with this regimen, which may be approaching saturation of the capacity for hepatic elimination.